Back to results
US 2011/0237530 A1Published application
Anti-xdr-tb drug, anti-mdr-tb drug, and combination anti-tuberculosis drug
AssigneesMicrobial Chemistry Research Foundation, Infectious Disease Research Institute
InventorsYOSHIAKI TAKAHASHI, Masayuki Igarashi, Masaji Okada
Life of this patent
Estimating the term…
Abstract
A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:
Claims3
A method for treating an individual infected with XDR-TB, the method comprising:
- administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:
A method for treating an individual infected with MDR-TB, the method comprising:
- administering to the individual an anti-MDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:
A method for treating an individual infected with drug-sensitive tuberculosis bacteria, the method comprising:
- administering to the individual a drug containing a compound having a structure expressed by Structural Formula (1) below and at least one anti-tuberculosis drug selected from an anti-tuberculosis drug containing rifampicin (RFP) and an anti-tuberculosis drug containing isonicotinic acid hydrazide (INH).
Dependencies are inferred from the claim text.